{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:34:56Z","timestamp":1793450096889,"version":"4.5.0"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bbi.2026.107017","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:25:30Z","timestamp":1789914330000},"page":"107017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Response to \u201cRoute of IL-4 administration in Li et al.: an inconsistency between the methods and Section 4.4\u201d"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3563-2377","authenticated-orcid":false,"given":"Zichao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3200-3517","authenticated-orcid":false,"given":"Zhaoming","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10268","key":"10.1016\/j.bbi.2026.107017_b0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bbi.2026.107017_b0010","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1161\/STROKEAHA.115.012079","article-title":"Interleukin-4 is essential for microglia\/macrophage M2 polarization and long-term recovery after cerebral ischemia","volume":"47","author":"Liu","year":"2016","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.bbi.2026.107017_b0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/brainsci6020018","article-title":"Neuroimmunology of the Interleukins 13 and 4","volume":"6","author":"Mori","year":"2016","journal-title":"Brain Sci."},{"issue":"1","key":"10.1016\/j.bbi.2026.107017_b0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11916-025-01365-4","article-title":"An update on CGRP Monoclonal antibodies for the preventive treatment of episodic migraine","volume":"29","author":"Nicol","year":"2025","journal-title":"Curr. Pain Headache Rep."},{"key":"10.1016\/j.bbi.2026.107017_b0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12974-014-0211-6","article-title":"Heterogeneous induction of microglia M2a phenotype by central administration of interleukin-4","volume":"11","author":"Pepe","year":"2014","journal-title":"J. Neuroinflammation"},{"issue":"16","key":"10.1016\/j.bbi.2026.107017_b0030","doi-asserted-by":"crossref","first-page":"12756","DOI":"10.3390\/ijms241612756","article-title":"The single-dose application of interleukin-4 ameliorates secondary brain damage in the early phase after moderate experimental traumatic brain injury in mice","volume":"24","author":"Walter","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"32","key":"10.1016\/j.bbi.2026.107017_b0035","doi-asserted-by":"crossref","first-page":"11281","DOI":"10.1523\/JNEUROSCI.1685-15.2015","article-title":"Neuronal interleukin-4 as a modulator of microglial pathways and ischemic brain damage","volume":"35","author":"Zhao","year":"2015","journal-title":"J. Neurosci."}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159126007658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159126007658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:20:24Z","timestamp":1793449224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159126007658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":7,"alternative-id":["S0889159126007658"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2026.107017","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to \u201cRoute of IL-4 administration in Li et al.: an inconsistency between the methods and Section 4.4\u201d","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2026.107017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2026.107018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107017"}}